TY - JOUR
T1 - Long-term use of benzodiazepines and nonbenzodiazepine hypnotics, 1999-2014
AU - Kaufmann, Christopher N.
AU - Spira, Adam P.
AU - Depp, Colin A.
AU - Mojtabai, Ramin
N1 - Funding Information:
Dr. Spira has agreed to serve as a consultant to Awarables, Inc., in support of a National Institutes of Health grant. The other authors report no financial relationships with commercial interests.
Funding Information:
Dr. Kaufmann and Dr. Depp are with the Department of Psychiatry, University of California, San Diego, La Jolla, California. Dr. Spira and Dr. Mojtabai are with the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore. Send correspondence to Dr. Kaufmann (e-mail: cnkaufmann@ucsd.edu). Dr. Kaufmann received funding from the University of California, San Diego, T32 Research Fellowship Program in Geriatric Mental Health (T32MH019934).
Publisher Copyright:
© Copyright 2018 American Psychiatric Association. All rights reserved.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Objective: Clinical guidelines suggest that benzodiazepines (BZDs) and non-BZD hypnotics (NBHs) be used on a shortterm basis. The authors examined trends in long-term BZD and NBH use from 1999 to 2014. Methods: Data included 82,091 respondents in the 1999-2014 waves of the National Health and Nutrition Examination Survey (NHANES). NHANES recorded medications used in the past 30 days on the basis of prescription bottles, and participants reported use duration. BZD and NBH use were categorized as short, medium, and long term, and time trends in use were assessed. Results: BZD and NBH use increased from 1999 to 2014, driven by increases in medium- and long-term use, even after adjustment for age and race-ethnicity. In most years, only a fifth of current BZD or NBH users reported short-term use. Conclusions: Long-term BZD and NBH use has grown independent of U.S. demographic shifts. Monitoring of use is needed to prevent adverse outcomes.
AB - Objective: Clinical guidelines suggest that benzodiazepines (BZDs) and non-BZD hypnotics (NBHs) be used on a shortterm basis. The authors examined trends in long-term BZD and NBH use from 1999 to 2014. Methods: Data included 82,091 respondents in the 1999-2014 waves of the National Health and Nutrition Examination Survey (NHANES). NHANES recorded medications used in the past 30 days on the basis of prescription bottles, and participants reported use duration. BZD and NBH use were categorized as short, medium, and long term, and time trends in use were assessed. Results: BZD and NBH use increased from 1999 to 2014, driven by increases in medium- and long-term use, even after adjustment for age and race-ethnicity. In most years, only a fifth of current BZD or NBH users reported short-term use. Conclusions: Long-term BZD and NBH use has grown independent of U.S. demographic shifts. Monitoring of use is needed to prevent adverse outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85041474061&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041474061&partnerID=8YFLogxK
U2 - 10.1176/appi.ps.201700095
DO - 10.1176/appi.ps.201700095
M3 - Review article
C2 - 29089011
AN - SCOPUS:85041474061
SN - 1075-2730
VL - 69
SP - 235
EP - 238
JO - Psychiatric Services
JF - Psychiatric Services
IS - 2
ER -